Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain Imaging in Alzheimer Disease. Cold Spring Harb Perspect Med. 2012 Apr. Vol 2:[Medline]. [Full Text].
Iverson DJ, Gronseth GS, Reger MA, Classen S, Dubinsky RM, Rizzo M, et al. Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Apr 20. 74 (16):1316-24. [Medline].
Rayment D, Biju M, Zheng R, Kuruvilla T. Neuroimaging in dementia: an update for the general clinician. Prog Neurol Psychiatry. 2016 Apr 7. Vol 20:[Full Text].
Nasrallah IM, Wolk DA. Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. J Nucl Med. 2014 Dec. 55 (12):2003-11. [Medline]. [Full Text].
Risacher SL, Saykin AJ. Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol. 2013 Sep. 33 (4):386-416. [Medline].
Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, et al, for ISTAART's NeuroImaging Professional Interest Area. Imaging markers for Alzheimer disease: which vs how. Neurology. 2013 Jul 30. 81 (5):487-500. [Medline].
Atri A. Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice. Handb Clin Neurol. 2016. 136:971-84. [Medline].
Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May 8. 56(9):1133-42. [Medline].
[Guideline] Iverson DJ, Gronseth GS, Reger MA, Classen S, Dubinsky RM, Rizzo M, et al. Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Apr 20. 74 (16):1316-24. [Medline]. [Full Text].
van de Pol LA, Korf ES, van der Flier WM, Brashear HR, Fox NC, Barkhof F. Magnetic resonance imaging predictors of cognition in mild cognitive impairment. Arch Neurol. 2007 Jul. 64(7):1023-8. [Medline].
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul. 34(7):939-44. [Medline].
Montagne A, Nation DA, Pa J, Sweeney MD, Toga AW, Zlokovic BV. Brain imaging of neurovascular dysfunction in Alzheimer's disease. Acta Neuropathol. 2016 May. 131 (5):687-707. [Medline].
Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007 May 22. 68(21):1809-14. [Medline].
Algotsson A, Winblad B. The integrity of the blood-brain barrier in Alzheimer's disease. Acta Neurol Scand. 2007 Jun. 115(6):403-8. [Medline].
Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007 May 15. 68(20):1718-25. [Medline].
Rodrigue KM, Kennedy KM, Devous MD Sr, et al. ß-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012 Feb 1. [Medline].
Carter SF, Scholl M, Almkvist O, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh Compound B and 18F-FDG. J Nucl Med. 2012 Jan. 53(1):37-46. [Medline].
Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011 Dec 6. 77(23):2034-42. [Medline]. [Full Text].
Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. J Alzheimers Dis. 2015. 45 (4):1077-88. [Medline].
Khan TK, Alkon DL. Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy. J Alzheimers Dis. 2015. 46 (4):817-36. [Medline].
Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement. 2015 Jan. 11 (1):58-69. [Medline].
Jagust WJ, Budinger TF, Reed BR. The diagnosis of dementia with single photon emission computed tomography. Arch Neurol. 1987 Mar. 44(3):258-62. [Medline].
Prados F, Cardoso MJ, Leung KK, Cash DM, Modat M. Measuring brain atrophy with a generalized formulation of the boundary shift integral. Neurobiol Aging. 2015 Jan. Vol 36:S81-S90. [Full Text].
Rana AK, Sandu AL, Robertson KL, McNeil CJ, Whalley LJ, Staff RT, et al. A comparison of measurement methods of hippocampal atrophy rate for predicting Alzheimer's dementia in the Aberdeen Birth Cohort of 1936. Alzheimers Dement (Amst). 2017. 6:31-39. [Medline]. [Full Text].
Bird JM, Levy R, Jacoby RJ. Computed tomography in the elderly: changes over time in a normal population. Br J Psychiatry. 1986 Jan. 148:80-5. [Medline].
Luxenberg JS, Haxby JV, Creasey H, et al. Rate of ventricular enlargement in dementia of the Alzheimer type correlates with rate of neuropsychological deterioration. Neurology. 1987 Jul. 37(7):1135-40. [Medline].
Frackowiak RS, Pozzilli C, Legg NJ, et al. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain. 1981 Dec. 104(Pt 4):753-78. [Medline].
Trollor JN, Sachdev PS, Haindl W, et al. Regional cerebral blood flow deficits in mild Alzheimer's disease using high resolution single photon emission computerized tomography. Psychiatry Clin Neurosci. 2005/06. 59(3):280-90.
Maruszak A, Thuret S. Why looking at the whole hippocampus is not enough-a critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer's disease diagnosis. Front Cell Neurosci. 2014. 8:95. [Medline].
Ferris SH, De Leon MJ, Wolf AP. Positron emission tomography in the study of aging and senile dementia. Neurobiol Aging. 1980. 1:127-31.
Del Sole A, Malaspina S, Magenta Biasina A. Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias. Funct Neurol. 2016 Oct/Dec. 31 (4):205-215. [Medline].
Schouten TM, Koini M, de Vos F, Seiler S, van der Grond J, Lechner A, et al. Combining anatomical, diffusion, and resting state functional magnetic resonance imaging for individual classification of mild and moderate Alzheimer's disease. Neuroimage Clin. 2016. 11:46-51. [Medline].
Lehmann M, Melbourne A, Dickson JC, Ahmed RM, Modat M, Cardoso MJ, et al. A novel use of arterial spin labelling MRI to demonstrate focal hypoperfusion in individuals with posterior cortical atrophy: a multimodal imaging study. J Neurol Neurosurg Psychiatry. 2016 Jan 5. [Medline].
Chow N, Hwang KS, Hurtz S, Green AE, Somme JH, Thompson PM, et al. Comparing 3T and 1.5T MRI for mapping hippocampal atrophy in the Alzheimer's Disease Neuroimaging Initiative. AJNR Am J Neuroradiol. 2015 Apr. 36 (4):653-60. [Medline].
Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet. 1996 Jul 13. 348(9020):94-7. [Medline].
Kesslak JP, Nalcioglu O, Cotman CW. Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology. 1991 Jan. 41(1):51-4. [Medline].
Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol. 2000 Apr. 47(4):430-9. [Medline].
Killiany RJ, Hyman BT, Gomez-Isla T, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002 Apr 23. 58(8):1188-96. [Medline].
Machulda MM, Ward HA, Borowski B, Gunter JL, Cha RH, O'Brien PC, et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology. 2003 Aug 26. 61(4):500-6. [Medline].
Sørensen L, Igel C, Liv Hansen N, Osler M, Lauritzen M, Rostrup E, et al. Early detection of Alzheimer's disease using MRI hippocampal texture. Hum Brain Mapp. 2016 Mar. 37 (3):1148-61. [Medline].
Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992 Oct. 55(10):967-72. [Medline].
Jack CR Jr, Petersen RC, O'Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology. 1992 Jan. 42(1):183-8. [Medline].
Jack CR Jr, Petersen RC, Xu YC, Waring SC, O'Brien PC, Tangalos EG, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology. 1997 Sep. 49(3):786-94. [Medline].
Frisoni GB, Laakso MP, Beltramello A, Geroldi C, Bianchetti A, Soininen H, et al. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease. Neurology. 1999 Jan 1. 52(1):91-100. [Medline].
Yeo JM, Lim X, Khan Z, Pal S. Systematic review of the diagnostic utility of SPECT imaging in dementia. Eur Arch Psychiatry Clin Neurosci. 2013 Oct. 263 (7):539-52. [Medline].
Johnson KA, Mueller ST, Walshe TM, English RJ, Holman BL. Cerebral perfusion imaging in Alzheimer's disease. Use of single photon emission computed tomography and iofetamine hydrochloride I 123. Arch Neurol. 1987 Feb. 44(2):165-8. [Medline].
DeKosky ST, Shih WJ, Schmitt FA, et al. Assessing utility of single photon emission computed tomography (SPECT) scan in Alzheimer disease: correlation with cognitive severity. Alzheimer Dis Assoc Disord. 1990. 4(1):14-23. [Medline].
Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May 8. 56(9):1143-53. [Medline].
Van Gool WA, Walstra GJ, Teunisse S, Van der Zant FM, Weinstein HC, Van Royen EA. Diagnosing Alzheimer's disease in elderly, mildly demented patients: the impact of routine single photon emission computed tomography. J Neurol. 1995 Jun. 242(6):401-5. [Medline].
Johnson KA, Holman BL, Rosen TJ, Nagel JS, English RJ, Growdon JH. Iofetamine I 123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer's disease. Arch Intern Med. 1990 Apr. 150(4):752-6. [Medline].
Claus JJ, van Harskamp F, Breteler MM, et al. The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer's disease: a population-based study. Neurology. 1994 Mar. 44(3 Pt 1):454-61. [Medline].
Holman BL, Johnson KA, Gerada B, Carvalho PA, Satlin A. The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT. J Nucl Med. 1992 Feb. 33(2):181-5. [Medline].
Bonte FJ, Weiner MF, Bigio EH, White CL 3rd. Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology. 1997 Mar. 202(3):793-7. [Medline].
Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol. 2007 Jul. 64(7):1015-20. [Medline].
Shimojo M, Higuchi M, Suhara T, Sahara N. Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging. Front Neurosci. 2015. 9:482. [Medline].
de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A. 2001 Sep 11. 98(19):10966-71. [Medline].
Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Aß aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012 Jan. 26(1):8-16. [Medline]. [Full Text].
Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011 Jan 19. 305(3):275-83. [Medline].
Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011 Nov. 68(11):1404-11. [Medline].
US Food and Drug Administration (FDA). FDA approves second brain imaging drug to help evaluate patients for Alzheimer's disease, dementia [press release]. October 25, 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm372261.htm. Accessed: October 25, 2013.
Neuraceq (florbetaben F 18) prescribing information. [package insert]. Matran Switzerland: Piramal Imaging, S.A. 2014.
Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Aß aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012 Jan. 26(1):8-16. [Medline]. [Full Text].
Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011 Jan 19. 305(3):275-83. [Medline].
Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011 Nov. 68(11):1404-11. [Medline].
Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001 Nov 7. 286(17):2120-7. [Medline].
Salmon E. Functional brain imaging applications to differential diagnosis in the dementias. Curr Opin Neurol. 2002 Aug. 15(4):439-44. [Medline].
Mazziotta JC, Frackowiak RS, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Semin Nucl Med. 1992 Oct. 22(4):233-46. [Medline].
Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000 May 23. 97(11):6037-42. [Medline].
Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A. 2001 Mar 13. 98(6):3334-9. [Medline].
Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995 Mar 22-29. 273(12):942-7. [Medline].
Teipel SJ, Kurth J, Krause B, Grothe MJ, Alzheimer's Disease Neuroimaging Initiative. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression. Neuroimage Clin. 2015. 8:583-93. [Medline].
Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 2002 Sep. 1(5):279-84. [Medline].
Messa C, Perani D, Lucignani G, Zenorini A, Zito F, Rizzo G, et al. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparison with fluorine-18-FDG PET. J Nucl Med. 1994 Feb. 35(2):210-6. [Medline].
Salmon E, Gregoire MC, Delfiore G, Lemaire C, Degueldre C, Franck G, et al. Combined study of cerebral glucose metabolism and [11C]methionine accumulation in probable Alzheimer's disease using positron emission tomography. J Cereb Blood Flow Metab. 1996 May. 16(3):399-408. [Medline].
Boxer AL, Rabinovici GD, Kepe V, Goldman J, Furst AJ, Huang SC. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology. 2007 Jul 17. 69(3):283-90. [Medline].
Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016 Mar 8. [Medline].
Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May 8. 56(9):1154-66. [Medline].